Charles River Laboratories International, Inc.

Charles River Laboratories International, Inc.'s next confirmed earnings release is scheduled for November 4, 2026.

As of June 30, 2026, Charles River Laboratories International, Inc. has 47.73M shares outstanding.

As of June 30, 2026, Charles River Laboratories International, Inc. maintains a current ratio of 1.35, meaning it holds 1.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 104.82, indicating elevated leverage, while an interest coverage ratio of 3.65 demonstrates adequate ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Charles River Laboratories International, Inc. posted a negative return on equity (ROE) of -7.70, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -3.16, reflecting losses generated across the asset base. The company generates approximately 3.53M in revenue per employee across its workforce of 19,800.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 8.60 indicates how many times Charles River Laboratories International, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Charles River Laboratories International, Inc. recorded 919.44M in income tax expense. The company reported a pretax loss of -3.21B and -4.17B in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 13, 2026, Charles River Laboratories International, Inc.'s stock has gained approximately 93.79% over the past 52 weeks.

Over the twelve months ended June 30, 2026, Charles River Laboratories International, Inc. generated 69.87B in revenue and converted that into -4.17B in net income, yielding earnings per share of -84.42. EBITDA reached 6.78B, while operating income came in at 8.14B.

As of June 30, 2026, Charles River Laboratories International, Inc. holds 3.35B in cash and equivalents against 52.90B in total debt, resulting in a net debt position of 42.42B. Total book value stands at 49.61B, with working capital of 6.89B providing operational flexibility.

Charles River Laboratories International, Inc. produced 10.17B in operating cash flow over the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Charles River Laboratories International, Inc. posted a gross margin of 32.67, reflecting its pricing power and cost economics. The operating margin of 11.66 and net profit margin of -5.96 provide insight into operational efficiency.